Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday.

pharma
Photo: Bloomberg
Press Trust of India New Delhi
2 min read Last Updated : May 17 2022 | 7:45 PM IST

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday.

The IPO received bids for 7,86,87,000 shares against 26,86,76,858 shares on offer, according to data available with NSE.

The category for Retail Individual Investors (RIIs) was subscribed 57 per cent and the portion for non-institutional investors attracted 6 per cent subscription.

The Initial Public Offer (IPO) has a fresh issue of equity shares aggregating to Rs 1,004 crore and an offer for sale of up to 11,85,07,493 equity shares.

As part of the OFS, Zuari Maroc Phosphates Pvt Ltd (ZMPPL) will offload 60,18,493 equity shares and the government of India will sell up to 11,24,89,000 equity shares.

The government will be offloading its entire 19.55 per cent stake in the company.

Currently, ZMPPL holds 80.45 per cent stake and the government of India owns the rest 19.55 per cent stake in the company.

The price range for the offer is at Rs 39-42 per share.

On Friday, Paradeep Phosphates said it has raised a little over Rs 450 crore from anchor investors.

Proceeds of fresh issue will be used to partly finance the acquisition of the fertiliser manufacturing facility in Goa and payment of debt and general corporate purposes.

Paradeep Phosphates is primarily engaged in manufacturing, trading, distribution and sales of a variety of complex fertilizers such as Di-Ammonium Phosphate (DAP) and NPK fertilizers.

JM Financial, SBI Capital Markets, ICICI Securities and Axis Capital are the managers to the offer.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Paradeep Phosphates Ltdpharma sctorspharmaceutical firms

First Published: May 17 2022 | 7:45 PM IST

Next Story